Developer docs
API playgroundTry for free, no card

Search company profiles

Archerfish Precision Diagnostics

Full company profile

uuid003fzg5

Namestring
Archerfish Precision Diagnostics
Legal namestring
Archerfish Precision Diagnostics Pte Ltd
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Archerfish Precision Diagnostics Pte Ltd is a Singapore-headquartered clinical molecular diagnostics laboratory formed in March 2025 through the merger of two CAP-accredited entities — Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories. The company operates from two Singapore sites (67 Ubi Avenue 1 and 1 Research Link on the NUS campus), employs 11–50 people, and positions itself as a regional platform serving both private and public healthcare sectors in Singapore and across Asia. Angsana brought commercialized molecular oncology capability (the first clinical NGS provider in Asia), while Pathnova contributed proprietary serology, AI-enhanced assays, and a nasopharyngeal carcinoma (NPC) early screening test focused on Asian-prevalent diseases.

The company's core technology stack combines Next-Generation Sequencing (NGS) for tumor mutation profiling, metagenomic NGS (mNGS) for infectious disease detection, AI-enhanced serology, serum proteomics via aptamer technology profiling thousands of proteins, and high-resolution LC-MS/MS. Service offerings include molecular oncology NGS, allergy and molecular allergology, NPC early screening, and contract research/consulting for pharma and biotech partners. Through distribution partnerships, the company also delivers third-party diagnostic products — notably the C2N Diagnostics PrecivityAD2 Alzheimer's blood test and ClearNote Health liquid biopsy assays — across Asia, with Singapore as the launch hub.

Revenue is generated via professional-services fees for laboratory testing (pricing is quote-based and not publicly disclosed), contract research and consulting for pharmaceutical clients, and distribution/licensing economics on partner-dispatched products. The business is backed by a consortium of Temasek-affiliated strategic investors (Temasek Life Sciences Laboratory, The Life Sciences Innovation Fund, Temasek Life Sciences Accelerator, and SEEDS Capital), and the company is targeting at least SGD $50 million over three years to fund technology development, commercialization, and regional expansion into seven or more additional Asian markets.

Short descriptiontext

Archerfish Precision Diagnostics is a Singapore-based CAP-accredited molecular diagnostics laboratory, formed in 2025 via merger of Angsana and Pathnova, offering NGS-based oncology, NPC screening, and allergy diagnostics, while distributing C2N and ClearNote products across Asia for healthcare providers, government systems, and pharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, next-generation sequencing, cancer screening tests, clinical laboratory services, precision diagnostics
Industry7 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Medical and Diagnostic Laboratories62151
SIC code4 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Diagnostic Laboratory Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Clinical Diagnostic Laboratory Services
TypeProfessional Services
Description

CAP-accredited laboratory testing services including molecular oncology, allergy diagnostics, and cancer screening tests offered to healthcare providers and patients in private and public healthcare sectors.

archerfishdx.com
2Contract Research Services
TypeProfessional Services
Description

Support for clinical research and trials tailored to specific needs of pharmaceutical and biotechnology partners, leveraging laboratory capabilities and expertise.

archerfishdx.com
3Consulting Services and Partnership
TypeProfessional Services
Description

Scientific expertise and collaborative partnerships offered to help partners achieve research and development goals in diagnostics.

archerfishdx.com
4Diagnostic Product Distribution
TypeLicensing Royalties
Description

Distribution of diagnostic products including ClearNote Health liquid biopsy tests and C2N Diagnostics PrecivityAD2 test across Asia through partnership agreements.

archerfishdx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Archerfish Precision Diagnostics operates two merged CAP-accredited clinical laboratories (Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories) providing molecular diagnostics services including NGS-based molecular oncology profiling, allergy and molecular allergology testing, and proprietary nasopharyngeal carcinoma (NPC) early screening. The company also offers contract research and consulting services to pharmaceutical and biotechnology partners. Through distribution partnerships, Archerfish extends its portfolio to include the C2N Diagnostics PrecivityAD2 blood test for Alzheimer's disease and ClearNote Health liquid biopsy tests across Asia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 90% accuracy compared to cerebrospinal fluid analysis or amyloid PET analysis in JAMA-published clinical care study (PrecivityAD2 test)
+2 more records
Product overview1 text field

Archerfish Precision Diagnostics operates as a molecular diagnostics laboratory offering a portfolio of clinical diagnostic services. The core service offerings include Molecular Oncology (NGS-based cancer mutation profiling), Allergy and Molecular Allergology, and Nasopharyngeal Carcinoma (NPC) Screening—these services originated from the merger of Angsana Molecular & Diagnostics Laboratory (NGS pioneer in Asia) and Pathnova Laboratories (serology and AI specialist). Supporting services include Contract Research and Consulting Services for industry partners. Through strategic partnerships, Archerfish distributes additional diagnostic products including the C2N Diagnostics PrecivityAD2™ blood test for Alzheimer's disease diagnosis and ClearNote Health liquid biopsy tests. Both constituent labs (Angsana and Pathnova) are CAP-accredited. The company is pursuing expansion into infectious disease detection via metagenomic NGS and data-driven disease detection through serum proteomics and serological profiling.

Product and service2 records
1Molecular Oncology (Next-Generation Sequencing)
CategoryCore diagnostic service
Description

Next-Generation Sequencing service that sequences numerous genes simultaneously to identify genetic mutations in tumors, enabling personalized cancer treatment selection. Offered to healthcare providers including hospitals and clinics.

2Allergy and Molecular Allergology
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-29
Description

Strategic partnership for distribution of ClearNote Health's liquid biopsy tests in Asia, beginning with Singapore as the regional launch hub. Archerfish will leverage its laboratory expertise and network to expand access to liquid biopsy testing across Asian markets.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

Partnership to distribute C2N's PrecivityAD2 blood test for Alzheimer's disease diagnosis across Singapore and Asia. The test demonstrates over 90% accuracy compared to cerebrospinal fluid or amyloid PET analysis. Archerfish is one of six international partners in C2N's global expansion targeting regions with inadequate PET infrastructure and aging populations.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

International partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

International partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

International partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.

6Medical Link
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

International partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.

biospace.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-08
Description

International partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeBroad incumbent
Description

US-listed liquid biopsy and NGS-based molecular diagnostics company with a broad oncology-focused menu. Comparable to Archerfish on NGS-based cancer testing technology and the ClearNote Health liquid biopsy distribution partnership that Archerfish represents across Asia.

TypeBroad incumbent
Description

China-headquartered genomics and molecular diagnostics provider with broad NGS-based clinical testing services across Asia. Directly comparable as a large-scale regional molecular diagnostics incumbent targeting similar oncology and infectious disease applications.

TypeDirect peer
Description

US-based clinical laboratory specializing in oncology-focused molecular diagnostics and NGS profiling for hospitals and clinicians. Closely comparable business model to Archerfish's molecular oncology NGS service serving healthcare providers.

TypeBroad incumbent
Description

Global medical laboratory operator with extensive Asia-Pacific presence providing clinical diagnostic services to hospitals and physicians. Comparable as a broad diagnostics lab incumbent competing with Archerfish's CAP-accredited clinical laboratory services across the region.

TypeEmerging player
Description

US developer of the PrecivityAD2 blood-based Alzheimer's diagnostic test that Archerfish distributes across Asia under partnership. Comparable technology (LC-MS/MS-based blood biomarker testing) and represents the innovator whose product Archerfish commercializes regionally.

TypeBroad incumbent
Description

US molecular diagnostics company specializing in cell-free DNA and NGS-based testing across oncology and reproductive health. Comparable on NGS-based liquid biopsy technology that overlaps with Archerfish's ClearNote Health partnership distribution.

7MGI Tech
TypeOthers
Description

Asia-based provider of NGS sequencing platforms and laboratory automation used by clinical diagnostics labs. Comparable as a regional technology infrastructure provider in the NGS ecosystem in which Archerfish operates its molecular oncology and mNGS services.

TypeDirect peer
Description

Asia-headquartered genomics services company providing NGS-based clinical and research testing across oncology, reproductive health, and infectious disease. Comparable to Archerfish on multi-omic NGS service menu, regional Asia presence, and clinical/research split.

TypeRegional player
Description

Singapore-based medical diagnostics laboratory serving hospitals and clinicians with clinical testing services. Most direct domestic peer competing with Archerfish in the Singapore private and public healthcare sector for molecular and specialty testing volume.

TypeEmerging player
Description

US-based liquid biopsy company whose tests Archerfish distributes across Asia via partnership. Comparable on liquid biopsy and NGS-based cancer detection technology underlying the products Archerfish sells to regional healthcare providers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Archerfish Precision Diagnostics

Clinical Diagnostic Laboratory Servicesarcherfishdx.com

Archerfish Precision Diagnostics is a Singapore-based CAP-accredited molecular diagnostics laboratory, formed in 2025 via merger of Angsana and Pathnova, offering NGS-based oncology, NPC screening, and allergy diagnostics, while distributing C2N and ClearNote products across Asia for healthcare providers, government systems, and pharma partners.

What Archerfish Precision Diagnostics does

Archerfish Precision Diagnostics Pte Ltd is a Singapore-headquartered clinical molecular diagnostics laboratory formed in March 2025 through the merger of two CAP-accredited entities — Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories. The company operates from two Singapore sites (67 Ubi Avenue 1 and 1 Research Link on the NUS campus), employs 11–50 people, and positions itself as a regional platform serving both private and public healthcare sectors in Singapore and across Asia. Angsana brought commercialized molecular oncology capability (the first clinical NGS provider in Asia), while Pathnova contributed proprietary serology, AI-enhanced assays, and a nasopharyngeal carcinoma (NPC) early screening test focused on Asian-prevalent diseases.

The company's core technology stack combines Next-Generation Sequencing (NGS) for tumor mutation profiling, metagenomic NGS (mNGS) for infectious disease detection, AI-enhanced serology, serum proteomics via aptamer technology profiling thousands of proteins, and high-resolution LC-MS/MS. Service offerings include molecular oncology NGS, allergy and molecular allergology, NPC early screening, and contract research/consulting for pharma and biotech partners. Through distribution partnerships, the company also delivers third-party diagnostic products — notably the C2N Diagnostics PrecivityAD2 Alzheimer's blood test and ClearNote Health liquid biopsy assays — across Asia, with Singapore as the launch hub.

Revenue is generated via professional-services fees for laboratory testing (pricing is quote-based and not publicly disclosed), contract research and consulting for pharmaceutical clients, and distribution/licensing economics on partner-dispatched products. The business is backed by a consortium of Temasek-affiliated strategic investors (Temasek Life Sciences Laboratory, The Life Sciences Innovation Fund, Temasek Life Sciences Accelerator, and SEEDS Capital), and the company is targeting at least SGD $50 million over three years to fund technology development, commercialization, and regional expansion into seven or more additional Asian markets.

Archerfish Precision Diagnostics firmographics

Firmographics
Name
Archerfish Precision Diagnostics
Legal name
Archerfish Precision Diagnostics Pte Ltd
Website
https://archerfishdx.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
Archerfish Precision Diagnostics is a Singapore-based CAP-accredited molecular diagnostics laboratory, formed in 2025 via merger of Angsana and Pathnova, offering NGS-based oncology, NPC screening, and allergy diagnostics, while distributing C2N and ClearNote products across Asia for healthcare providers, government systems, and pharma partners.
Ownership category
akta.pro rank

Archerfish Precision Diagnostics industry classification

Industry
Product category
Clinical Diagnostic Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Molecular diagnostics
  • Next-generation sequencing
  • Cancer screening tests
  • Clinical laboratory services
  • Precision diagnostics

Where Archerfish Precision Diagnostics is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices2 records

Markets served

Archerfish Precision Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Clinical Diagnostic Laboratory Services: CAP-accredited laboratory testing services including molecular oncology, allergy diagnostics, and cancer screening tests offered to healthcare providers and patients in private and public healthcare sectors.
  2. Contract Research Services: Support for clinical research and trials tailored to specific needs of pharmaceutical and biotechnology partners, leveraging laboratory capabilities and expertise.
  3. Consulting Services and Partnership: Scientific expertise and collaborative partnerships offered to help partners achieve research and development goals in diagnostics.
  4. Diagnostic Product Distribution: Distribution of diagnostic products including ClearNote Health liquid biopsy tests and C2N Diagnostics PrecivityAD2 test across Asia through partnership agreements.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Archerfish Precision Diagnostics product offering

Product offering

Core offering

Archerfish Precision Diagnostics operates two merged CAP-accredited clinical laboratories (Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories) providing molecular diagnostics services including NGS-based molecular oncology profiling, allergy and molecular allergology testing, and proprietary nasopharyngeal carcinoma (NPC) early screening. The company also offers contract research and consulting services to pharmaceutical and biotechnology partners. Through distribution partnerships, Archerfish extends its portfolio to include the C2N Diagnostics PrecivityAD2 blood test for Alzheimer's disease and ClearNote Health liquid biopsy tests across Asia.

Product overview

Archerfish Precision Diagnostics operates as a molecular diagnostics laboratory offering a portfolio of clinical diagnostic services. The core service offerings include Molecular Oncology (NGS-based cancer mutation profiling), Allergy and Molecular Allergology, and Nasopharyngeal Carcinoma (NPC) Screening—these services originated from the merger of Angsana Molecular & Diagnostics Laboratory (NGS pioneer in Asia) and Pathnova Laboratories (serology and AI specialist). Supporting services include Contract Research and Consulting Services for industry partners. Through strategic partnerships, Archerfish distributes additional diagnostic products including the C2N Diagnostics PrecivityAD2™ blood test for Alzheimer's disease diagnosis and ClearNote Health liquid biopsy tests. Both constituent labs (Angsana and Pathnova) are CAP-accredited. The company is pursuing expansion into infectious disease detection via metagenomic NGS and data-driven disease detection through serum proteomics and serological profiling.

Differentiator

Problem solved

Functional benefit

Products and services

  • Molecular Oncology (Next-Generation Sequencing) Next-Generation Sequencing service that sequences numerous genes simultaneously to identify genetic mutations in tumors, enabling personalized cancer treatment selection. Offered to healthcare providers including hospitals and clinics.
  • Allergy and Molecular Allergology

Quantifiable outcome

  • Over 90% accuracy compared to cerebrospinal fluid analysis or amyloid PET analysis in JAMA-published clinical care study (PrecivityAD2 test)
  • +2 more outcomes

Companies that use Archerfish Precision Diagnostics

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Archerfish Precision Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Archerfish Precision Diagnostics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • ClearNote HealthcoreChannel Partner/ Reseller/ Distributor · 29 October 2025Strategic partnership for distribution of ClearNote Health's liquid biopsy tests in Asia, beginning with Singapore as the regional launch hub. Archerfish will leverage its laboratory expertise and network to expand access to liquid biopsy testing across Asian markets.
  • C2N DiagnosticscoreChannel Partner/ Reseller/ Distributor · 8 August 2025Partnership to distribute C2N's PrecivityAD2 blood test for Alzheimer's disease diagnosis across Singapore and Asia. The test demonstrates over 90% accuracy compared to cerebrospinal fluid or amyloid PET analysis. Archerfish is one of six international partners in C2N's global expansion targeting regions with inadequate PET infrastructure and aging populations.
  • Accuserv Diagnostic CenterminorChannel Partner/ Reseller/ Distributor · 8 August 2025International partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.
  • Codex GeneticsminorChannel Partner/ Reseller/ Distributor · 8 August 2025International partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.
  • Dr. Dangs LabminorChannel Partner/ Reseller/ Distributor · 8 August 2025International partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.
  • Medical LinkminorChannel Partner/ Reseller/ Distributor · 8 August 2025International partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.
  • Milenia LabsminorChannel Partner/ Reseller/ Distributor · 8 August 2025International partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.

Scale indicators4 records

Recent moves1 record

Archerfish Precision Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • Guardant Health: US-listed liquid biopsy and NGS-based molecular diagnostics company with a broad oncology-focused menu. Comparable to Archerfish on NGS-based cancer testing technology and the ClearNote Health liquid biopsy distribution partnership that Archerfish represents across Asia.
  • BGI Genomics: China-headquartered genomics and molecular diagnostics provider with broad NGS-based clinical testing services across Asia. Directly comparable as a large-scale regional molecular diagnostics incumbent targeting similar oncology and infectious disease applications.
  • Sonic Healthcare: Global medical laboratory operator with extensive Asia-Pacific presence providing clinical diagnostic services to hospitals and physicians. Comparable as a broad diagnostics lab incumbent competing with Archerfish's CAP-accredited clinical laboratory services across the region.
  • Natera: US molecular diagnostics company specializing in cell-free DNA and NGS-based testing across oncology and reproductive health. Comparable on NGS-based liquid biopsy technology that overlaps with Archerfish's ClearNote Health partnership distribution.

Direct peers

  • NeoGenomics: US-based clinical laboratory specializing in oncology-focused molecular diagnostics and NGS profiling for hospitals and clinicians. Closely comparable business model to Archerfish's molecular oncology NGS service serving healthcare providers.
  • Novogene: Asia-headquartered genomics services company providing NGS-based clinical and research testing across oncology, reproductive health, and infectious disease. Comparable to Archerfish on multi-omic NGS service menu, regional Asia presence, and clinical/research split.

Emerging players

  • C2N Diagnostics: US developer of the PrecivityAD2 blood-based Alzheimer's diagnostic test that Archerfish distributes across Asia under partnership. Comparable technology (LC-MS/MS-based blood biomarker testing) and represents the innovator whose product Archerfish commercializes regionally.
  • ClearNote Health: US-based liquid biopsy company whose tests Archerfish distributes across Asia via partnership. Comparable on liquid biopsy and NGS-based cancer detection technology underlying the products Archerfish sells to regional healthcare providers.

Others

  • MGI Tech: Asia-based provider of NGS sequencing platforms and laboratory automation used by clinical diagnostics labs. Comparable as a regional technology infrastructure provider in the NGS ecosystem in which Archerfish operates its molecular oncology and mNGS services.

Regional players

  • Innoquest Diagnostics: Singapore-based medical diagnostics laboratory serving hospitals and clinicians with clinical testing services. Most direct domestic peer competing with Archerfish in the Singapore private and public healthcare sector for molecular and specialty testing volume.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights6 records

Customer concentration

Archerfish Precision Diagnostics social profiles

Digital presence

Archerfish Precision Diagnostics compliance and trust

Trust signal

Compliance1 record

Archerfish Precision Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Archerfish Precision Diagnostics leadership team

Management profile

Number of profiles

Profiles7 records

Archerfish Precision Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Archerfish Precision Diagnostics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Archerfish Precision Diagnostics

What does Archerfish Precision Diagnostics do?

Archerfish Precision Diagnostics operates two merged CAP-accredited clinical laboratories (Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories) providing molecular diagnostics services including NGS-based molecular oncology profiling, allergy and molecular allergology testing, and proprietary nasopharyngeal carcinoma (NPC) early screening. The company also offers contract research and consulting services to pharmaceutical and biotechnology partners. Through distribution partnerships, Archerfish extends its portfolio to include the C2N Diagnostics PrecivityAD2 blood test for Alzheimer's disease and ClearNote Health liquid biopsy tests across Asia.

Is Archerfish Precision Diagnostics a public or private company?

Archerfish Precision Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Archerfish Precision Diagnostics founded?

Archerfish Precision Diagnostics was founded in 2025. It employs 11 to 50 people.

Where is Archerfish Precision Diagnostics based?

Archerfish Precision Diagnostics is headquartered in Singapore, Singapore, in the Asia region.

How does Archerfish Precision Diagnostics make money?

Four revenue lines are on record. Clinical Diagnostic Laboratory Services are the primary driver. The others are contract Research Services, consulting Services and Partnership and diagnostic Product Distribution.

Who are Archerfish Precision Diagnostics's main competitors?

Broad incumbents on record are Guardant Health, BGI Genomics, Sonic Healthcare and Natera. Direct peers are NeoGenomics and Novogene. Emerging players are C2N Diagnostics and ClearNote Health. MGI Tech is listed as an others. Innoquest Diagnostics is listed as a regional player.

Does Archerfish Precision Diagnostics have an API?

No public API is recorded for Archerfish Precision Diagnostics.

What industry is Archerfish Precision Diagnostics in?

Archerfish Precision Diagnostics's product category is Clinical Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceC2N Announces Major Global Expansion, Adds Six New International PartnersC2N Diagnostics announced the expansion of its PrecivityAD2™ blood test for Alzheimer's disease diagnosis to over seven additional countries through six new international partnerships with clinical reference laboratories and distributors. The new partners include Accuserv Diagnostic Center, Archerfish Precision Diagnostics, Codex Genetics, Dr. Dangs Lab, Medical Link, and Milenia Labs, with the company targeting regions facing inadequate PET infrastructure and growing healthcare pressures from aging populations. The blood test has demonstrated over 90% accuracy compared to cerebrospinal fluid analysis or amyloid PET analysis in a JAMA-published clinical care study.Life Science Company NewsArcherfish Precision Diagnostics and C2N Diagnostics collaborate to provide advanced Alzheimer's diagnostics in Singapore and AsiaArcherfish Precision Diagnostics and C2N Diagnostics announced a partnership to introduce C2N's PrecivityAD2 blood test for Alzheimer's disease in Singapore and Asia. The test detects amyloid beta and tau peptides via a single blood draw, offering a less invasive alternative to traditional methods. The collaboration aims to improve early diagnosis for Singapore's ageing population.Asia Business OutlookArcherfish & C2N Launch Breakthrough Alzheimer's Blood Test in SingaporeArcherfish Precision Diagnostics and C2N Diagnostics launched Singapore's first blood-based Alzheimer's test, PrecivityAD2, using liquid chromatography and mass spectrometry to detect amyloid pathology. The test targets individuals aged 55 and older, offering a non-invasive alternative to conventional diagnostics. The partnership aims to enable early intervention amid Singapore's ageing population.